IL-6 can lead to upregulation of PD-1 and immune exhaustion (104), while promoting interleukin 17 (IL-17) production – which can be a disadvantage in patients with cancer to subduing T-cell activity and augmenting tumor cell proliferation (105–107). This evidence concerns the gene PDCD1 and neoplasm.